RCUS Q2 2022 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$27M+185.4% YoY

Gross Profit

$27M100.0% margin

Operating Income

-$69M-255.6% margin

Net Income

-$67M-248.1% margin

EPS (Diluted)

$-0.90

QoQ Revenue Growth

+50.0%

Cash Flow

Operating Cash Flow

-$65M

Free Cash Flow

-$72M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$729M

Stockholders' Equity

$747M

Cash & Equivalents

$273M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$27M	$9M	+185.4%
Gross Profit	$27M	$9M	+185.4%
Operating Income	-$69M	-$76M	+9.4%
Net Income	-$67M	-$76M	+11.8%

Revenue Segments

License and Development Services for All Gilead Programs

$17M62%

Gilead Access Rights

$8M31%

Taiho Access Rights

$2M7%